Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 18

1.

Mismatch repair system in endometriotic tissue and eutopic endometrium of unaffected women.

Grassi T, Calcagno A, Marzinotto S, Londero AP, Orsaria M, Canciani GN, Beltrami CA, Marchesoni D, Mariuzzi L.

Int J Clin Exp Pathol. 2015 Feb 1;8(2):1867-77.

2.

Randomized phase III clinical trial comparing the combination of capecitabine and oxaliplatin (CAPOX) with the combination of 5-fluorouracil, leucovorin and oxaliplatin (modified FOLFOX6) as adjuvant therapy in patients with operated high-risk stage II or stage III colorectal cancer.

Pectasides D, Karavasilis V, Papaxoinis G, Gourgioti G, Makatsoris T, Raptou G, Vrettou E, Sgouros J, Samantas E, Basdanis G, Papakostas P, Bafaloukos D, Kotoula V, Kalofonos HP, Scopa CD, Pentheroudakis G, Fountzilas G.

BMC Cancer. 2015 May 10;15:384. doi: 10.1186/s12885-015-1406-7.

3.
4.

Heterogenous mismatch-repair status in colorectal cancer.

Joost P, Veurink N, Holck S, Klarskov L, Bojesen A, Harbo M, Baldetorp B, Rambech E, Nilbert M.

Diagn Pathol. 2014 Jun 26;9:126. doi: 10.1186/1746-1596-9-126.

5.

Genetic testing strategies in newly diagnosed endometrial cancer patients aimed at reducing morbidity or mortality from lynch syndrome in the index case or her relatives.

Stewart A Phd.

PLoS Curr. 2013 Sep 16;5. pii: ecurrents.eogt.b59a6e84f27c536e50db4e46aa26309c. doi: 10.1371/currents.eogt.b59a6e84f27c536e50db4e46aa26309c.

6.

History, genetics, and strategies for cancer prevention in Lynch syndrome.

Kastrinos F, Stoffel EM.

Clin Gastroenterol Hepatol. 2014 May;12(5):715-27; quiz e41-3. doi: 10.1016/j.cgh.2013.06.031. Review.

7.

High-level microsatellite instability in appendiceal carcinomas.

Taggart MW, Galbincea J, Mansfield PF, Fournier KF, Royal RE, Overman MJ, Rashid A, Abraham SC.

Am J Surg Pathol. 2013 Aug;37(8):1192-200. doi: 10.1097/PAS.0b013e318282649b.

8.

Comparison of the clinical prediction model PREMM(1,2,6) and molecular testing for the systematic identification of Lynch syndrome in colorectal cancer.

Kastrinos F, Steyerberg EW, BalmaƱa J, Mercado R, Gallinger S, Haile R, Casey G, Hopper JL, LeMarchand L, Lindor NM, Newcomb PA, Thibodeau SN, Syngal S; Colon Cancer Family Registry..

Gut. 2013 Feb;62(2):272-9. doi: 10.1136/gutjnl-2011-301265.

9.

Implementing screening for Lynch syndrome among patients with newly diagnosed colorectal cancer: summary of a public health/clinical collaborative meeting.

Bellcross CA, Bedrosian SR, Daniels E, Duquette D, Hampel H, Jasperson K, Joseph DA, Kaye C, Lubin I, Meyer LJ, Reyes M, Scheuner MT, Schully SD, Senter L, Stewart SL, St Pierre J, Westman J, Wise P, Yang VW, Khoury MJ.

Genet Med. 2012 Jan;14(1):152-62. doi: 10.1038/gim.0b013e31823375ea.

10.

Strategies to identify the Lynch syndrome among patients with colorectal cancer: a cost-effectiveness analysis.

Ladabaum U, Wang G, Terdiman J, Blanco A, Kuppermann M, Boland CR, Ford J, Elkin E, Phillips KA.

Ann Intern Med. 2011 Jul 19;155(2):69-79. doi: 10.7326/0003-4819-155-2-201107190-00002.

11.
12.

The genetic basis of colorectal cancer in a population-based incident cohort with a high rate of familial disease.

Woods MO, Younghusband HB, Parfrey PS, Gallinger S, McLaughlin J, Dicks E, Stuckless S, Pollett A, Bapat B, Mrkonjic M, de la Chapelle A, Clendenning M, Thibodeau SN, Simms M, Dohey A, Williams P, Robb D, Searle C, Green JS, Green RC.

Gut. 2010 Oct;59(10):1369-77. doi: 10.1136/gut.2010.208462.

13.

Risk of urothelial bladder cancer in Lynch syndrome is increased, in particular among MSH2 mutation carriers.

van der Post RS, Kiemeney LA, Ligtenberg MJ, Witjes JA, Hulsbergen-van de Kaa CA, Bodmer D, Schaap L, Kets CM, van Krieken JH, Hoogerbrugge N.

J Med Genet. 2010 Jul;47(7):464-70. doi: 10.1136/jmg.2010.076992.

14.

Mismatch repair protein expression and colorectal cancer in Hispanics from Puerto Rico.

De Jesus-Monge WE, Gonzalez-Keelan C, Zhao R, Hamilton SR, Rodriguez-Bigas M, Cruz-Correa M.

Fam Cancer. 2010 Jun;9(2):155-66. doi: 10.1007/s10689-009-9310-4.

15.

A review on the molecular diagnostics of Lynch syndrome: a central role for the pathology laboratory.

van Lier MG, Wagner A, van Leerdam ME, Biermann K, Kuipers EJ, Steyerberg EW, Dubbink HJ, Dinjens WN.

J Cell Mol Med. 2010 Jan;14(1-2):181-97. doi: 10.1111/j.1582-4934.2009.00977.x. Review.

16.

Genetic variants in XRCC2: new insights into colorectal cancer tumorigenesis.

Curtin K, Lin WY, George R, Katory M, Shorto J, Cannon-Albright LA, Smith G, Bishop DT, Cox A, Camp NJ; Colorectal Cancer Study Group..

Cancer Epidemiol Biomarkers Prev. 2009 Sep;18(9):2476-84. doi: 10.1158/1055-9965.EPI-09-0187.

17.

Deficient mismatch repair system in patients with sporadic advanced colorectal cancer.

Koopman M, Kortman GA, Mekenkamp L, Ligtenberg MJ, Hoogerbrugge N, Antonini NF, Punt CJ, van Krieken JH.

Br J Cancer. 2009 Jan 27;100(2):266-73. doi: 10.1038/sj.bjc.6604867.

18.

Tumor characteristics as an analytic tool for classifying genetic variants of uncertain clinical significance.

Hofstra RM, Spurdle AB, Eccles D, Foulkes WD, de Wind N, Hoogerbrugge N, Hogervorst FB; IARC Unclassified Genetic Variants Working Group..

Hum Mutat. 2008 Nov;29(11):1292-303. doi: 10.1002/humu.20894.

Items per page

Supplemental Content

Support Center